Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 1Lung Neoplasms 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 13Carboplatin 13Docetaxel 11Cisplatin 11pembrolizumab 9Paclitaxel 8Gemcitabine 7Erlotinib Hydrochloride 4Bevacizumab 4anlotinib 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Gefitinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2cemiplimab 2auricularum 2atezolizumab 2apatinib 2Vemurafenib 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Ramucirumab 2Calcium Dobesilate 2trametinib 1toripalimab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Non-Small-Cell Lung × CTLA-4 Antigen × Clear all
NCT04929041 2026-05-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

National Cancer Institute (NCI)

Phase 2/3 Suspended
427 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡